Thirty-First Annual Symposium

Description
This program is designed to provide attendees with practical information about recent developments, current practices, controversies and laboratory management issues relative to transfusion medicine.

Who Should Attend
This program will be of interest to all healthcare providers who participate in the collection, production, transfusion and monitoring of blood products.

Learning Objectives
Upon the completion of this activity, participants should be able to:

• Describe the relative risks and short and long-term adverse effects of bone marrow harvest versus peripheral blood stem collection for the donor.
• Recognize differences in hematopoietic stem cell recipient outcomes such as acute and chronic graft-versus-host disease, graft rejection, relapse and non-relapse mortality, and overall survival following bone marrow versus peripheral blood stem transplantation in both the unrelated and related donor settings.
• Describe the current status of the development of induced pluripotent stem (iPS) cell therapies including the potential use of blood and umbilical cord blood as sources for generating iPS cells.
• Develop appropriate patient and donor care strategies from examples described during case reviews.
• List the challenges of establishing a national blood supply in a war torn emerging country.
• Explain the role of autoantibodies in dilated cardiomyopathy (DCM) and describe the evidence supporting the use of apheresis in the treatment of DCM.
• Describe bedside to bench development of targeted therapies in multiple myeloma.
• Discuss the principle of bloodless medicine and its evolution to patient blood management.
• Describe appropriate transfusion support in patients with Sickle Cell Disease.
• Summarize a new class of molecular diseases in humans.

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Red Cross Biomedical Services (ARCBS) and the National Institutes of Health. ARCBS is accredited by the ACCME to provide continuing medical education for physicians and provides continuing education credits through its SUCCESS™ Program.

Designation Statement
TThe American Red Cross Biomedical Services designates this educational activity for a maximum of 6.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. A maximum of 6.25 SUCCESS™ CEU credits will be awarded to laboratory professionals participating in this activity.

Level of Instruction
Intermediate to Advanced

Disclaimer
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of ARCBS. Information is presented for educational purposes only.

Disclosure Statement
All faculty participating in ARCBS continuing medical education programs are expected to disclose to learners whether they do or do not have any real or apparent conflicts(s) of interest or other relationships related to the content of their presentation(s). Faculty are also expected to disclose off-label and/or investigational uses of products under discussion.

We gratefully acknowledge The American Fluoroseal Corporation for providing an educational grant in support of this continuing medical education activity.